WO2002066506A3 - Use of casb7439 (ash2) in the immunotherapy of breast cancer - Google Patents

Use of casb7439 (ash2) in the immunotherapy of breast cancer Download PDF

Info

Publication number
WO2002066506A3
WO2002066506A3 PCT/EP2002/001649 EP0201649W WO02066506A3 WO 2002066506 A3 WO2002066506 A3 WO 2002066506A3 EP 0201649 W EP0201649 W EP 0201649W WO 02066506 A3 WO02066506 A3 WO 02066506A3
Authority
WO
WIPO (PCT)
Prior art keywords
casb7439
breast cancer
ash2
immunotherapy
disclosed
Prior art date
Application number
PCT/EP2002/001649
Other languages
French (fr)
Other versions
WO2002066506A2 (en
Inventor
Y De Bassols Carlota Vinals
Jean-Pol Cassart
Original Assignee
Glaxosmithkline Biolog Sa
Y De Bassols Carlota Vinals
Jean-Pol Cassart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Y De Bassols Carlota Vinals, Jean-Pol Cassart filed Critical Glaxosmithkline Biolog Sa
Priority to AU2002249221A priority Critical patent/AU2002249221A1/en
Publication of WO2002066506A2 publication Critical patent/WO2002066506A2/en
Publication of WO2002066506A3 publication Critical patent/WO2002066506A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

The use of CASB7439 polypeptides and polynucleotides, and variants, immunogenic fragments and fusions thereof, and of immunogenic compositions thereof, in the prophylaxis, treatment and diagnosis of breast tumours is disclosed. Methods of diagnosing the presence of breast cancer or a susceptility to breast cancer in a subject related to the expression or activity of a CASB7439 polynucleotide or polypeptide are also disclosed.
PCT/EP2002/001649 2001-02-21 2002-02-15 Use of casb7439 (ash2) in the immunotherapy of breast cancer WO2002066506A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002249221A AU2002249221A1 (en) 2001-02-21 2002-02-15 Use of casb7439 (ash2) in the immunotherapy of breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0104259.7 2001-02-21
GBGB0104259.7A GB0104259D0 (en) 2001-02-21 2001-02-21 Novel compounds

Publications (2)

Publication Number Publication Date
WO2002066506A2 WO2002066506A2 (en) 2002-08-29
WO2002066506A3 true WO2002066506A3 (en) 2002-12-19

Family

ID=9909202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001649 WO2002066506A2 (en) 2001-02-21 2002-02-15 Use of casb7439 (ash2) in the immunotherapy of breast cancer

Country Status (3)

Country Link
AU (1) AU2002249221A1 (en)
GB (1) GB0104259D0 (en)
WO (1) WO2002066506A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111974D0 (en) * 2001-05-16 2001-07-04 Glaxosmithkline Biolog Sa Novel Compounds
EA020617B1 (en) * 2009-05-27 2014-12-30 Глаксосмитклайн Байолоджикалс С.А. Casb7439 constructs
CA2834365A1 (en) 2011-04-28 2012-11-01 Sandia Corporation Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002828A2 (en) * 1999-07-07 2001-01-11 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002828A2 (en) * 1999-07-07 2001-01-11 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERTHET F.-X. ET AL.: "Applied genome research in the field of human vaccines", JOURNAL OF BIOTECHNOLOGY, vol. 85, no. 2, 13 February 2001 (2001-02-13), pages 213 - 226, XP002214628 *
DATABASE SWISS-PROT [online] "ASH_2 HUMAN", XP002214631, retrieved from EMBL Database accession no. q99929 *
KOBAYASHI H. ET AL.: "Defining promiscuous MHC class II Helper T-cell epitopes for the Her2/neu Tumor Antigen", CANCER RESEARCH, vol. 60, 15 September 2000 (2000-09-15), pages 5228 - 5236, XP002214629 *

Also Published As

Publication number Publication date
WO2002066506A2 (en) 2002-08-29
AU2002249221A1 (en) 2002-09-04
GB0104259D0 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
ATE420175T1 (en) C-TYPE LECTIN TRANSMEMBRANE ANTIGEN EXPRESSED IN HUMAN PROSTATE CANCER AND USES THEREOF
WO2001057081A3 (en) Narc-1, subtilase-like homologs
WO2004058146A3 (en) Novel compositions and methods in cancer
WO2004060304A3 (en) Novel compositions and methods in cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2002066506A3 (en) Use of casb7439 (ash2) in the immunotherapy of breast cancer
LT2002070A (en) Polynucleotide encoding rg1 polypeptide
WO2003080808A3 (en) Novel compositions and methods in cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
IL207012A (en) Pharmaceutical composition comprising sgp28 and a vaccine composition for the treatment of a cancer expressing sgp28
WO2000061753A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2003039484A3 (en) Novel compositions and methods for cancer
WO2002098913A3 (en) Polypeptides and corresponding polynucleotides for prophylaxis and treatment of colon cancer
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
WO2004060301A3 (en) Novel compositions and methods in cancer
WO2001021653A3 (en) Ovarian tumor antigen and methods of use therefor
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
AU4174201A (en) 103p2d6: tissue specific protein highly expressed in various cancers
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
IL210928A0 (en) Antibodies specific for 238p1b2 and uses thereof
WO2002066601A3 (en) Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam2
WO2002068587A3 (en) Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP